Rosetta Genomics this week unveiled two new microRNA-based tests under development, one a kidney cancer diagnostic and the other a mesothelioma prognosis assay, and disclosed that it will be building up an in-house sales force to market them and certain of its other second-generation products.

View full post on Yahoo! News Search Results for mesothelioma